US Reform Bills "Losing Sight Of Cost Controls"

14 August 1994

The current focus in the US health care reform debate on universal coverage has obscured another goal of the program, cost control, disappointing many consumer groups, business executives and labor leaders who joined the battle for health care legislation specifically for that reason.

Some feel the spreading unease could have mid-term political consequences for President Clinton and long-range implications for any economy which will spend about $1 trillion, or 14% of its Gross Domestic Product, on health care. The Congressional Budget Office says that share will grow to 20% in 2003 under current law. Cost-control advocates fear that as the administration seeks votes, some cost restraints in the current bills may be weakened and benefits added.

Representative Richard Gephardt's bill would control costs through fee limits on doctors and hospitals if market forces did not slow the growth of health spending to the rate of growth of the overall economy. Senator George Mitchell's bill contains no controls on health prices, costs or spending but seeks to slow spending growth through a new tax on health plans whose costs grow faster than a prescribed pace and by encouraging competition. Senator Robert Dole said his plan has no mandates or controls but would be financed by Medicare and medicaid cutbacks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight